Provided by Tiger Trade Technology Pte. Ltd.

Lyell Immunopharma, Inc.

21.96
-1.8400-7.73%
Volume:62.06K
Turnover:1.39M
Market Cap:465.95M
PE:-0.97
High:23.65
Open:23.65
Low:21.80
Close:23.80
52wk High:45.00
52wk Low:7.65
Shares:21.22M
Float Shares:14.04M
Volume Ratio:0.87
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-22.7500
EPS(LYR):-26.2348
ROE:-75.75%
ROA:-24.16%
PB:1.42
PE(LYR):-0.84

Loading ...

Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know

TIPRANKS
·
Feb 28

Keros Therapeutics Adds Veteran Finance Leader to Board

TIPRANKS
·
Feb 27

Lyell Immunopharma Announces Participation in March Investor Conferences

GlobeNewswire
·
Feb 23

Lyell Immunopharma Launches Phase 3 Trial Comparing Ronde-cel to Approved CAR T Therapies in Large B-Cell Lymphoma

Reuters
·
Feb 12

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-to-Head Car T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

THOMSON REUTERS
·
Feb 12

Lyell Immunopharma Inc - Bla Submission Expected in 2027

THOMSON REUTERS
·
Feb 12

Lyell Immunopharma VP Veronica Sanchez Bulis Reports Sale of Common Shares

Reuters
·
Jan 07

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:04 PM

Reuters
·
Dec 23, 2025

Lyell Immunopharma Shares Rise After HC Wainwright Upgrade

MT Newswires Live
·
Dec 10, 2025

BUZZ-H.C. Wainwright upgrades Lyell to 'buy' on cell therapy progression

Reuters
·
Dec 09, 2025

Lyell Immunopharma Raised to Buy From Neutral by HC Wainwright & Co.

Dow Jones
·
Dec 09, 2025

HC Wainwright Upgrades Lyell Immunopharma to Buy From Neutral, Adjusts PT to $45 From $20

MT Newswires Live
·
Dec 09, 2025

Lyell Immunopharma Inc : H.c. Wainwright Raises to Buy From Neutral; Raises Target Price to $45 From $20

THOMSON REUTERS
·
Dec 09, 2025

Lyell Immunopharma Reports High Response Rates for Ronde-Cel in Large B-Cell Lymphoma Trial

Reuters
·
Dec 08, 2025

Lyell Immunopharma Presents New Clinical Data From Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients With Large B-Cell Lymphoma at the 67TH Ash Annual Meeting and Exposition

THOMSON REUTERS
·
Dec 08, 2025

Lyell Immunopharma Files for Proposed Resale From Time to Time by Innovative Cellular Therapeutics Holdings Limited of up to 1.9 Mln Shares

THOMSON REUTERS
·
Dec 06, 2025

Lyell Immunopharma Updates Bylaws on Stockholder Proposals and Voting Standards

Reuters
·
Dec 06, 2025

Lyell Immunopharma Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
Nov 24, 2025

Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) one-year returns climbed after last week's 13% gain, institutional investors must be happy

Simply Wall St.
·
Nov 22, 2025

Lyell Immunopharma Q3 Sales $15.000K Down From $34.000K YoY

Benzinga
·
Nov 13, 2025